Robert Francomano insider trades: Stemline Therapeutics (STML) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 4, 2020 | STML | ↓ Sell | 272 | $11.51 | $3K | Direct | May 6, 2020 (2d) |
| Mar 9, 2020 | STML | ↓ Sell | 1,266 | $5.00 | $6K | Direct | Mar 13, 2020 (4d) |
| Feb 7, 2020 | STML | ↓ Sell | 5,064 | $6.72 | $34K | Direct | Feb 14, 2020 (7d) |
| Dec 27, 2019 | STML | ↓ Sell | 2,670 | $10.84 | $29K | Direct | Jan 3, 2020 (7d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Robert Francomano's insider trades
Robert Francomano is Chief Commercial Officer at Stemline Therapeutics (STML). Since Dec 27, 2019, Robert has reported no open-market purchases and 4 sales worth $72K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (4 filings), other transactions (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every STML insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.